SUBOXONE, (buprenorphine/naloxone), treatment of opioid dependence.
PSYCHIATRY - Focus
Opinions on drugs - Posted on Sep 10 2015
Reason for request
Renewal of inclusion
- SUBOXONE, a combination of high-dose buprenorphine (HDB) and naloxone, has Marketing Authorisation in the substitution treatment of opioid drug dependence, within the framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse.
- Treatment is intended for use only in adults and adolescents over 15 years of age who have agreed to be treated for addiction.
- This is an additional therapeutic tool, used mainly on the first prescription of HDB in intravenous drug addicts who have been informed of the special features and limitations of the medicinal product and who wish to have a medicinal aid of this kind.
Improvement in actual benefit
Évaluation des médicaments